Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJan 23, 2026
DataAggregated Company Financials
Companies21
  • 7D6.2%
  • 3M11.4%
  • 1Y-27.8%
  • YTD15.8%

In the last week, the Healthcare industry is up 6.2%, with Novo Nordisk up 8.6%. However, the industry is down 28% over the past year. Earnings are forecast to grow by 4.8% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 23 Jan 2026DKK 2.3tDKK 453.8bDKK 136.9b18.7x16.5x5x
Sun, 21 Dec 2025DKK 1.9tDKK 453.8bDKK 136.9b16.9x13.7x4.1x
Tue, 18 Nov 2025DKK 1.9tDKK 454.1bDKK 137.0b17.1x13.8x4.2x
Thu, 16 Oct 2025DKK 2.1tDKK 447.6bDKK 141.7b18.3x15x4.7x
Sat, 13 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.4x4.6x
Mon, 11 Aug 2025DKK 1.9tDKK 434.8bDKK 132.5b28.7x14.2x4.3x
Wed, 09 Jul 2025DKK 2.5tDKK 423.0bDKK 124.5b30.7x19.7x5.8x
Fri, 06 Jun 2025DKK 2.6tDKK 423.7bDKK 124.6b30.8x20.7x6.1x
Sun, 04 May 2025DKK 2.5tDKK 409.3bDKK 121.3b23x20.6x6.1x
Tue, 01 Apr 2025DKK 2.6tDKK 409.5bDKK 121.3b23.1x21.1x6.2x
Thu, 27 Feb 2025DKK 3.4tDKK 410.0bDKK 121.4b28.8x28x8.3x
Sat, 25 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.4x29.8x8.6x
Mon, 23 Dec 2024DKK 3.1tDKK 387.4bDKK 111.3b28.7x28.2x8.1x
Wed, 20 Nov 2024DKK 3.8tDKK 387.3bDKK 111.3b32.1x33.8x9.7x
Fri, 18 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.3x39.2x11.3x
Sun, 15 Sep 2024DKK 4.7tDKK 372.0bDKK 107.1b36x43.8x12.6x
Tue, 13 Aug 2024DKK 4.6tDKK 370.3bDKK 107.0b36.1x42.6x12.3x
Thu, 11 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.6x46.3x13.9x
Sat, 08 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b36.2x46.5x13.9x
Mon, 06 May 2024DKK 4.3tDKK 354.8bDKK 106.4b33.9x40.9x12.3x
Wed, 03 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b38.4x44.7x13.1x
Fri, 01 Mar 2024DKK 4.2tDKK 340.1bDKK 98.9b38.2x42.9x12.5x
Sun, 28 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b34.7x42x11.8x
Tue, 26 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.2x11.3x
Thu, 23 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b32.7x40.4x11.4x
Sat, 21 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.8x42.6x11.5x
Mon, 18 Sep 2023DKK 3.5tDKK 305.5bDKK 82.2b36.6x42.9x11.5x
Wed, 16 Aug 2023DKK 3.3tDKK 301.3bDKK 81.0b40x40.9x11x
Fri, 14 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b38.3x38x10x
Sun, 11 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40x39.9x10.5x
Tue, 09 May 2023DKK 3.2tDKK 284.0bDKK 74.5b40.3x42.5x11.1x
Thu, 06 Apr 2023DKK 3.0tDKK 272.4bDKK 68.5b39.4x43.5x10.9x
Sat, 04 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b39.4x40.7x9.6x
Mon, 30 Jan 2023DKK 2.7tDKK 275.9bDKK 66.3b37x40.4x9.7x
Price to Earnings Ratio

40.4x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 66.3bTotal Revenue: DKK 275.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 16.5x which is lower than its 3-year average PE of 33.6x.
  • The 3-year average PS ratio of 9.4x is higher than the industry's current PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market2.64%
Healthcare6.22%
Pharma8.09%
Life Sciences0.96%
Healthcare Services0.26%
Biotech-0.50%
Medical Equipment-2.49%
Healthtech-6.03%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 270x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 103% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 396.708.6%
+DKK 140.0b		-31.7%PE17x
ZEAL Zealand PharmaDKK 433.706.5%
+DKK 1.9b		-41.8%PE4.7x
DEMANT DemantDKK 234.201.3%
+DKK 639.0m		-19.5%PE18.7x
GUBRA GubraDKK 467.801.7%
+DKK 127.5m		-23.8%PE4.4x
BAVA Bavarian NordicDKK 200.000.6%
+DKK 75.9m		1.7%PE6.4x

Latest News

ALK B
DKK 220.80
ALK-Abelló
7D
-0.9%
1Y
42.1%

ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly

Jan 23
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
DEMANT
DKK 234.20
Demant
7D
1.3%
1Y
-19.5%

An Intrinsic Calculation For Demant A/S (CPH:DEMANT) Suggests It's 24% Undervalued

Jan 22
An Intrinsic Calculation For Demant A/S (CPH:DEMANT) Suggests It's 24% Undervalued
NNIT
DKK 46.80
NNIT
7D
-5.0%
1Y
-50.7%

NNIT: Higher Margins And CEO Transition Will Support Future Upside Potential

Analysts have trimmed their price target on NNIT from DKK 75 to about DKK 62.50, as updated assumptions reflect a higher discount rate, more moderate revenue growth, stronger profit margins, and a lower future P/E multiple. What's in the News CEO Pär Fors has decided to leave NNIT for personal family reasons and will remain in the role until the end of July 2026 or until a new CEO is appointed, whichever comes first (Key Developments).
BAVA
DKK 200.00
Bavarian Nordic
7D
0.6%
1Y
1.7%

BAVA: Vaccine Preparedness Contracts And Buybacks Will Support Stronger Long Term Earnings

Analysts have kept their price target for Bavarian Nordic steady at €250.00. They cite a slightly higher assumed discount rate, a smaller expected revenue decline of around 5%, a higher projected profit margin of about 17%, and a lower future P/E assumption near 23x as key inputs behind the unchanged view.
GMAB
DKK 2,118.00
Genmab
7D
-2.1%
1Y
40.1%

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
NOVO B
DKK 396.70
Novo Nordisk
7D
8.6%
1Y
-31.7%

Novo Nordisk A/S' (CPH:NOVO B) 26% Share Price Surge Not Quite Adding Up

Jan 17
Novo Nordisk A/S' (CPH:NOVO B) 26% Share Price Surge Not Quite Adding Up
HLUN B
DKK 44.36
H. Lundbeck
7D
-1.6%
1Y
8.5%

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly

Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
AMBU B
DKK 88.55
Ambu
7D
-1.8%
1Y
-35.1%

AMBU B: Share Buybacks And Dividend Policy Will Support Future Upside

Analysts now set Ambu's price target at €139, down from €147, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that adjust their valuation framework. What's in the News Ambu A/S is set to be removed from the OMX Copenhagen 20 Index, which may affect how some index and benchmark focused investors view or hold the stock (Key Developments).
EMBLA
DKK 32.00
Embla Medical hf
7D
-1.8%
1Y
-7.8%

EMBLA: Ukraine Program And Buybacks Will Support Future Margin Stability

Analysts have kept their fair value estimate for Embla Medical hf unchanged at €34.00. They have updated assumptions around discount rate, revenue growth, profit margins and future P/E to reflect a slightly different balance of risk and profitability in their models.
ZEAL
DKK 433.70
Zealand Pharma
7D
6.5%
1Y
-41.8%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
COLO B
DKK 553.00
Coloplast
7D
-4.1%
1Y
-32.3%

COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside

Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.
GUBRA
DKK 467.80
Gubra
7D
1.7%
1Y
-23.8%
SMSMED
DKK 3.80
Scandinavian Medical Solutions
7D
0.3%
1Y
-28.3%
BIOPOR
DKK 1.01
BioPorto
7D
-3.4%
1Y
-34.1%
STENO
DKK 1.49
Stenocare
7D
4.2%
1Y
65.0%
CHEMM
DKK 703.50
ChemoMetec
7D
0.5%
1Y
38.9%